Related Experiment Videos
Therapy of ischemic cardiomyopathy with pentoxifylline
1Department of Internal Medicine, Marshall University School of Medicine, Huntington Veterans Administration Medical Center, West Virginia.
Insights
Pentoxifylline improved exercise capacity and reduced symptoms in patients with ischemic cardiomyopathy. This blood flow-improving drug may benefit heart function by enhancing coronary perfusion.
Area of Science:
- Cardiology
- Hemodynamics
- Pharmacology
Background:
- Abnormal blood rheology is characteristic of coronary artery disease.
- Ischemic cardiomyopathy involves left ventricular dysfunction and obstructed coronary arteries.
- Blood flow properties significantly impact cardiac function and patient outcomes.
Purpose of the Study:
- To evaluate the effects of pentoxifylline on exercise capacity, ejection fraction, and symptoms in patients with ischemic cardiomyopathy.
- To assess the safety and tolerability of pentoxifylline in this patient population.
Main Methods:
- A study involving 9 patients with ischemic cardiomyopathy and significant coronary artery obstruction.
- Administration of pentoxifylline 400 mg three times daily for twelve weeks.
- Assessment of ejection fraction, exercise tolerance (treadmill test), anginal symptoms, and dyspnea on exertion before and after therapy.
Main Results:
- Seven out of 9 patients showed improvements in ejection fraction and exercise tolerance.
- Mean ejection fraction increased by 9.8% (p = .07) and treadmill time by 15% (p = .27).
- Significant improvements were observed in anginal symptoms (p > .001) and dyspnea on exertion (p = .03).
Conclusions:
- Pentoxifylline may offer benefits for patients with ischemic cardiomyopathy.
- Improvements in hemorheologic properties may enhance coronary perfusion and cardiac function.
- Pentoxifylline was well-tolerated in this study group.
Abstract:
Abnormal blood rheology is a known characteristics of coronary artery disease. The authors evaluated the effects of pentoxifylline on the exercise capacity ejection fraction and symptoms of 9 patients with ischemic cardiomyopathy. All patients had signs and symptoms of left ventricular dysfunction. All had at least two major vessels obstructed as determined by coronary angiography. Pentoxifylline 400 mg three times daily was administered for twelve weeks. Seven of 9 patients responded with increases in ejection fraction and exercise tolerance. Exercise tolerance correlated with improvement or lack of improvement in ejection fraction. For all patients at twelve weeks post-therapy mean ejection fraction increased 9.8% over baseline (p = .07), total treadmill time increased 15% (p = .27), and mean double product increased 13% (p = .03). Anginal symptoms were significantly improved over baseline at twelve weeks of therapy (p greater than .001), as well as dyspnea on exertion (p = .03). Pentoxifylline was well tolerated. Pentoxifylline may benefit ischemic cardiomyopathy by improving coronary perfusion owing to favorable alterations in hemorheologic properties.